Ascletis Gets Record Funding From China’s Hangzhou Development Zone For HIV/AIDs Drug Research
This article was originally published in PharmAsia News
Hangzhou National Hi-Tech Industrial Development Zone awarded U.S.-China hybrid Ascletis a $1.6 million grant to fund research for HIV/AIDs drugs, the highest amount paid to date by a program aimed at wooing top Chinese national research talent back home.
You may also be interested in...
Already well-funded Chinese venture Ascletis has completed a large Series B to support the commercialization of effective new oral HCV drugs and progress its pipeline, and has not ruled out the possibility of going public in an IPO.
Ascletis Opens Its $100 Million Wallet - Breaks Ground On China Facility, Sets Sights On In-Licensing
HANGZHOU, China - U.S.-China hybrid Ascletis Inc. is putting some of its $100 million Series A funding to immediate use, breaking ground Oct. 20 on a facility in Zhenjiang Province that will house its China headquarters and R&D center
SHANGHAI - Beijing-based biotech startup BeiGene Ltd. announced its first in-licensing deal this month for two clinical-stage oncology compounds from Janssen Pharmaceutical NV, a division of Johnson & Johnson.